Proteomics to diagnose human tumors and provide prognostic information

ONCOLOGY

Volumn 18, Issue 4, 2004, Pages 521-529

  Ornstein, David K ^a   Petricoin III, Emmanuel F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR PROTEIN;

EARLY DIAGNOSIS; GENETICS; HUMAN; METHODOLOGY; MICRODISSECTION; NEOPLASM; PROGNOSIS; PROTEOMICS; REVIEW;

EARLY DIAGNOSIS; HUMANS; MICRODISSECTION; NEOPLASM PROTEINS; NEOPLASMS; PROGNOSIS; PROTEOMICS;

EID: 4544380907     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Petricoin EF, Liotta LA: Mass spectrometry-based diagnostics: The upcoming revolution in disease detection. Clin Chem 49:533-534, 2003.
2. Petricoin EF, Zoon KC, Kohn EC et al: Clinical proteomics: Translating benchside promise into bedside reality. Nat Rev Drug Discov 1:683-695, 2002.
3. Ornstein DK, Gillespie JW, Paweletz CP, et al: Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21:2235-2242, 2000.
4. Celis A, Rasmussen HH, Celis P, et al: Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis 20:355-361, 1999.
5. Bonner RF, Emmert-Buck M, Cole K, et al: Laser capture microdissection: Molecular analysis of tissue. Science 278:1481, 1483, 1997.
6. Emmert-Buck MR, Bonner RF, Smith PD, et al: Laser capture microdissection. Science 274:998-1001, 1996.
7. Ornstein DK, Englert C, Gillespie JW, et al: Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium. Clin Cancer Res 6:353-356, 2000.
8. Hoogland C, Sanchez JC, Tonella L, et al: The SWISS-2DPAGE database: What has changed during the last year. Nucleic Acids Res 27:289-291, 1999.
9. Hoogland C, Sanchez JC, Tonella L, et al: Current status of the SWISS-2D-PAGE database. Nucleic Acids Res 26:332-333, 1998.
10. Berndt P, Hobohm U, Langen H: Reliable automatic protein identification from matrix-assisted laser desorption/ionization mass spectrometric peptide fingerprints. Electrophoresis 20:3521-3526, 1999.
11. Abram M, Best CJ, Flaig MJ, et al: Proteomic analysis of human prostate cancer. Mol Carcinog 33:9-15, 2002.
12. Celis JE, Celis P, Palsdottir H, et al: Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol Cell Proteomics 1:269-279, 2002.
13. Zhang LY, Ying WT, Mao YS, et al: Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol 9:650-654, 2003.
14. Meehan KL, Holland JW, Dawkins HJ: Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 50:54-63, 2002.
15. Zhang R, Tremblay TL, McDermid A, et al: Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia 42:194-208, 2003.
16. Seow TK, Ong SE, Liang RC, et al: Two-dimensional electrophoresis map of the human hepatocellular carcinoma cell line, HCC-M, and identification of the separated proteins by mass spectrometry. Electrophoresis 21:1787-1813, 2000.
17. Emmert-Buck MR, Gillespie JW, Paweletz CP, et al: An approach to proteomic analysis of human tumors. Mol Carcinog 27:158-165, 2000.
18. Paweletz CP, Ornstein DK, Roth MJ, et al: Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 60:6293-6297, 2000.
19. Kang JS, Calvo BF, Maygarden SJ, et al: Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin Cancer Res 8:117-123, 2002.
20. Jones MB, Krutzsch H, Shu H, et al: Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2:76-84, 2002.
21. Unlu M, Morgan ME, Minden JS: Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 18:2071-2077, 1997.
22. Zhou G, Li H, DeCamp D, et al: 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 1:117-124, 2002.
23. Gygi SP, Rist B, Gerber SA, et al: Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17:994-999, 1999.
24. Han DK, Eng J, Zhou H, et al: Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat Biotechnol 19:946-951, 2001.
25. Smolka M, Zhou H, Aebersold R: Quantitative protein profiling using two-dimensional gel electrophoresis, isotope-coded affinity tag labeling, and mass spectrometry. Mol Cell Proteomics 1:19-29, 2002.
26. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847, 1998.
27. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624-629, 2002.
28. Rhodes DR, Sanda MG, Otte AP, et al: Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95:661-668, 2003.
29. Kim D, Gregory CW, Smith GJ, et al: Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry 35:2-10, 1999.
30. Gaston KE, Kim D, Singh S, et al: Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 170:990-993, 2003.
31. Liotta LA, Espina V, Mehta AI, et al: Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell 3:317-325, 2003.
32. Paweletz CP, Charboneau L, Bichsel VE, et al: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981-1989, 2001.
33. Davies HA: The ProteinChip System from Ciphergen: A new technique for rapid, microscale protein biology. J Mol Med 8:B29, 2000.
34. Issaq HJ, Conrads TP, Prieto DA, et al: SELDI-TOF MS for diagnostic proteomics. Anal Chem 75:148A-155A, 2003.
35. von Eggeling F, Junker K, Fiedle W, et al: Mass spectrometry meets chip technology: A new proteomic tool in cancer research? Electrophoresis 22:2898-2902, 2001.
36. Wulfkuhle JD, Liotta LA, Petricoin EF: Proteomic applications for the early detection of cancer. Nat Rev Cancer 3:267-275, 2003.
37. Paweletz CP, Trock B, Pennanen M, et al: Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 17:301-307, 2001.
38. Cazares LH, Adam BL, Ward MD, et al: Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 8:2541-2552, 2002.
39. Petricoin EF, Ardekani AM, Hitt BA, et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577, 2002.
40. Conrads TP, Zhou M, Petricoin EF, et al: Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn 3:411-420, 2003.
41. Petricoin EF, Ornstein DK, Paweletz CP, et al: Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94:1576-1578, 2002.
42. Adam BL, Qu Y, Davis JW, et al: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62:3609-3614, 2002.